Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Profit After Tax (2016 - 2025)

Marker Therapeutics has reported Profit After Tax over the past 11 years, most recently at -$1.7 million for Q4 2025.

  • Quarterly Profit After Tax rose 55.62% to -$1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.2 million through Dec 2025, down 13.35% year-over-year, with the annual reading at -$12.2 million for FY2025, 13.35% down from the prior year.
  • Profit After Tax was -$1.7 million for Q4 2025 at Marker Therapeutics, up from -$2.0 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $3.1 million in Q4 2023 and troughed at -$13.2 million in Q4 2022.
  • The 5-year median for Profit After Tax is -$4.2 million (2025), against an average of -$5.1 million.
  • Year-over-year, Profit After Tax soared 148.08% in 2023 and then tumbled 225.05% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$9.8 million in 2021, then tumbled by 35.18% to -$13.2 million in 2022, then surged by 123.25% to $3.1 million in 2023, then tumbled by 225.05% to -$3.8 million in 2024, then soared by 55.62% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Profit After Tax are -$1.7 million (Q4 2025), -$2.0 million (Q3 2025), and -$4.0 million (Q2 2025).